THORATEC'S BI-VENTRICULAR ASSIST DEVICE INDICATION FOR EMERGENCY CASES
This article was originally published in The Gray Sheet
Executive Summary
THORATEC'S BI-VENTRICULAR ASSIST DEVICE INDICATION FOR EMERGENCY CASES would give the company entrance to a niche market for which no other ventricular assist devices are approved. At a Dec. 5 meeting in Gaithersburg, Maryland, FDA's Circulatory System Devices Panel unanimously voted to recommend approval of the device as a bridge-to-transplant as long as certain labeling changes are made and postmarket surveillance performed.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.